The Global Acquired Aplastic Anemia Market Is Expected To Reach USD 10,246.1 Million By 2030 At 4.20% CAGR During The Forecast Period 2022-2030.

Acquired Aplastic Anemia Market Overview:

Increasing prevalence of hematological diseases is expected to drive the global aplastic anemia market. For example, according to the Centers for Disease Control and Prevention, hemophilia A affects 1 in 5,000 male newborns, and about 400 babies are born with hemophilia A each year. The estimated incidence of hemophilia is 1 in 12,000 annually. Additionally, increasing awareness of aplastic anemia and hematological diseases will fuel the growth of the global market.

For example, the International Foundation for Aplastic Anemia and MDS, NORD – National Organization for Rare Disorders, Inc., and CancerIndex are spreading awareness of aplastic anemia. The Aplastic Anemia Trust Spring Awareness Campaign was launched in February 2019. Additionally, increasing government support for research and development, lifestyle changes, and rapid technological developments are expected to propel the market growth during the forecast period.

Additionally, rising prevalence of rare diseases, growing demand for better treatments, increasing investments in biotech and pharmaceutical industries for R&D, and availability of funds drive the market growth. However, high cost of treatment may slow the market growth during that period. Treatment cost is a major factor influencing treatment choice. A bone marrow transplant can cost more than US$300,000. Therefore, high cost of treatment is likely to hamper the growth of the aplastic anemia therapeutics market.

Acquired Aplastic Anemia Market size, estimates and forecasts are provided in terms of sales volume (K units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Acquired Aplastic Anemia Market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.

Key Market Updates:

• In November 2018, the U.S. Food and Drug Administration (FDA) approved Promacta, a first-line treatment for aplastic anemia. Published by Novartis AG. Novartis AG has also received approval for Revolade for use in the treatment of aplastic anemia in adult patients.
• In September 2016, Regen BioPharma Inc. submitted an additional data application for the orphan drug HemaXelerate. HemaXellerate builds up the patient's adipose tissue cells and helps induce the body's response to heal the bone marrow and restore its ability to produce new, healthy blood cells.

Major Market Segments Covered in Acquired Aplastic Anemia Market Industry Research:

Market Key Players:
Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), CSL Limited (Australia), Amgen Inc., GlaxoSmithKline plc., Bluebird bio.

By Type:

• Diagnosis
• Treatment

By Application:

• Hospitals
• Clinics
• Other

By Region:

Americas dominate the global acquired aplastic anemia market owing to well-developed technology, increasing number of patients with hematologic disorders, rising prevalence of cancer, high healthcare expenditure, and increasing government support for research and development. Additionally, increase in R&D activities and concentration of major companies boosted the market growth in this region.

Europe holds the second position in the global acquired aplastic anemia market owing to government R&D support and availability of research funding. This is expected to continue to drive the European market over the forecast period. For example, countries like Germany and France are increasing their investments in healthcare.

Asia Pacific is the fastest-growing acquired aplastic anemia market owing to rapidly advancing medical technology, huge patient population, and high healthcare expenditure. It is also likely to emerge as the fastest-growing market globally, with growing demand for new treatment modalities in countries such as India and South Korea. Moreover, increasing demand for high-quality devices in the healthcare sector is expected to lead to the use of advanced equipment, which in turn will boost the acquired aplastic anemia market growth in this region.

Meanwhile, in the Middle East and Africa, blood diseases have become a major problem due to limited screening, ignorance of the disease, and lack of access to treatment.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

Driver

The acquired aplastic anemia market is expected to grow at a significant rate during the forecast period. The growth of this market can be attributed to the increasing prevalence of acquired aplastic anemia and growing awareness of the condition. Additionally, availability of treatment options and increasing healthcare expenditures are also expected to contribute to the market growth. As the prevalence of AE increases, the incidence of acquired aplastic anemia is increasing worldwide. Additionally, availability of treatment options and increasing healthcare expenditures are also expected to contribute to the market growth.

Acquired Aplastic Anemia Market report scope:

Key Takeaways from this Acquired Aplastic Anemia Market Report

• Estimate Acquired Aplastic Anemia Market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, applications and by different industry verticals.
• Understand the supply chain in depth on the value growth at each step, in order to optimize value and bring effectiveness in your processes.
• Know the different dynamics affecting the market - challenges, key driving factors and opportunities.
• Get a quick viewpoint on the Acquired Aplastic Anemia Market entropy - M&A's, deals, partnerships, product launches of all key companies for the historical 5 years.
• Estimate the supply-demand gaps, import-export data and regulatory landscape for more than top 20 countries worldwide for the market.
• Get complete insights on your competitor performance - market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
• Study the sales and distribution channels over key geographies to improve top-line revenues.

Frequently Asked Questions-

What is the CAGR of Acquired Aplastic Anemia Market?

The Acquired Aplastic Anemia Market is growing at a CAGR of 4.20% During Forecast Period.

 What are the key types of Acquired Aplastic Anemia Market?

Diagnosis, Treatment

What are the key applications of Acquired Aplastic Anemia Market?

Hospitals, Clinics, Other                                                             

Who are the key players in Acquired Aplastic Anemia Market?

Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), CSL Limited (Australia), Amgen Inc., GlaxoSmithKline plc., Bluebird bio.